Human Papillomavirus Genotypes in High-Grade Cervical Lesions in the United States

Background. Two vaccines protect against human papillomaviruses (HPV) 16 and 18, which cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ (CIN2+). Monitoring HPV types in CIN2+ may be used to assess HPV vaccine impact. Methods. As part of a mult...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2012-12, Vol.206 (12), p.1878-1886
Main Authors: Hariri, Susan, Unger, Elizabeth R., Powell, Suzanne E., Bauer, Heidi M., Bennett, Nancy M., Bloch, Karen C., Niccolai, Linda M., Schafer, Sean, Steinau, Martin, Markowitz, Lauri E.
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adolescent
Adult
Age Factors
Age groups
Biological and medical sciences
Biopsy
Cervical cancer
Cervical intraepithelial neoplasia
DNA, Viral - genetics
DNA, Viral - isolation & purification
Ethnic Groups
Female
Fundamental and applied biological sciences. Psychology
Genotype
Genotypes
Hispanics
Human papillomavirus
Humans
Infections
Infectious diseases
Lesions
Medical sciences
Microbiology
Miscellaneous
Papillomaviridae - classification
Papillomaviridae - genetics
Papillomaviridae - isolation & purification
Papillomavirus Infections - complications
Papillomavirus Infections - epidemiology
Papillomavirus Infections - pathology
Papillomavirus Infections - virology
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - immunology
Preventive medicine
United States - epidemiology
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - prevention & control
Uterine Cervical Neoplasms - virology
Vaccination
Virology
VIRUSES
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Two vaccines protect against human papillomaviruses (HPV) 16 and 18, which cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ (CIN2+). Monitoring HPV types in CIN2+ may be used to assess HPV vaccine impact. Methods. As part of a multisite vaccine impact monitoring project (HPV-IMPACT), biopsy specimens used to diagnose CIN2+ were obtained for HPV DNA typing for women aged 18-39 years. Results. Among 4,121 CIN2+ cases reported during 2008-2009 in 18-to 39-year-old women 3058 (74.2%) were tested; 96% were HPV DNA positive. HPV 16 was most common (49.1%), followed by HPV 31 (10.4%) and HPV 52 (9.7%). HPV 18 prevalence was 5.5% overall. Proportion of CIN2+ cases associated with HPV 16/18 was highest (56.3%) in 25-to 29-year-old women. HPV 16/18-associated lesions were less common in non-Hispanic blacks (41.9%) and Hispanics (46.3%) compared with non-Hispanic whites (59.1%) (P
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jis627